IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-28769-9.html
   My bibliography  Save this article

ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer’s disease models

Author

Listed:
  • Yuanyuan Zhao

    (Case Western Reserve University School of Medicine)

  • Di Hu

    (Case Western Reserve University School of Medicine)

  • Rihua Wang

    (Case Western Reserve University School of Medicine)

  • Xiaoyan Sun

    (Case Western Reserve University School of Medicine)

  • Philip Ropelewski

    (Case Western Reserve University School of Medicine)

  • Zita Hubler

    (Case Western Reserve University School of Medicine)

  • Kathleen Lundberg

    (Case Western Reserve University School of Medicine)

  • Quanqiu Wang

    (Case Western Reserve University School of Medicine)

  • Drew J. Adams

    (Case Western Reserve University School of Medicine)

  • Rong Xu

    (Case Western Reserve University School of Medicine)

  • Xin Qi

    (Case Western Reserve University School of Medicine)

Abstract

Predisposition to Alzheimer’s disease (AD) may arise from lipid metabolism perturbation, however, the underlying mechanism remains elusive. Here, we identify ATPase family AAA-domain containing protein 3A (ATAD3A), a mitochondrial AAA-ATPase, as a molecular switch that links cholesterol metabolism impairment to AD phenotypes. In neuronal models of AD, the 5XFAD mouse model and post-mortem AD brains, ATAD3A is oligomerized and accumulated at the mitochondria-associated ER membranes (MAMs), where it induces cholesterol accumulation by inhibiting gene expression of CYP46A1, an enzyme governing brain cholesterol clearance. ATAD3A and CYP46A1 cooperate to promote APP processing and synaptic loss. Suppressing ATAD3A oligomerization by heterozygous ATAD3A knockout or pharmacological inhibition with DA1 restores neuronal CYP46A1 levels, normalizes brain cholesterol turnover and MAM integrity, suppresses APP processing and synaptic loss, and consequently reduces AD neuropathology and cognitive deficits in AD transgenic mice. These findings reveal a role for ATAD3A oligomerization in AD pathogenesis and suggest ATAD3A as a potential therapeutic target for AD.

Suggested Citation

  • Yuanyuan Zhao & Di Hu & Rihua Wang & Xiaoyan Sun & Philip Ropelewski & Zita Hubler & Kathleen Lundberg & Quanqiu Wang & Drew J. Adams & Rong Xu & Xin Qi, 2022. "ATAD3A oligomerization promotes neuropathology and cognitive deficits in Alzheimer’s disease models," Nature Communications, Nature, vol. 13(1), pages 1-20, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28769-9
    DOI: 10.1038/s41467-022-28769-9
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-28769-9
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-28769-9?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Yuanyuan Zhao & Xiaoyan Sun & Di Hu & Domenick A. Prosdocimo & Charles Hoppel & Mukesh K. Jain & Rajesh Ramachandran & Xin Qi, 2019. "ATAD3A oligomerization causes neurodegeneration by coupling mitochondrial fragmentation and bioenergetics defects," Nature Communications, Nature, vol. 10(1), pages 1-20, December.
    2. Natasha Chandiramani & Xianhong Wang & Marta Margeta, 2011. "Molecular Basis for Vulnerability to Mitochondrial and Oxidative Stress in a Neuroendocrine CRI-G1 Cell Line," PLOS ONE, Public Library of Science, vol. 6(1), pages 1-18, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28769-9. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.